Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
The advent of precision medicine has brought light to the treatment of non-small cell lung cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting therapy through genetic and epigenetic cues. Tumor driver genes in NSCLC patients have been uncovered one by one, including e...
Main Authors: | Jiajia Wu, Zhenghong Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/23/15056 |
Similar Items
-
Dysregulated Metabolism in EGFR-TKI Drug Resistant Non-Small-Cell Lung Cancer: A Systematic Review
by: Julia Babuta, et al.
Published: (2022-07-01) -
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
by: Georgia Gomatou, et al.
Published: (2023-01-01) -
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01) -
Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery
by: Olga Furman, et al.
Published: (2022-07-01) -
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
by: Shenduo Li, et al.
Published: (2023-05-01)